BCAN

BCAN (brevican/BEHAB) is a brain-specific chondroitin sulfate proteoglycan of the hyaluronan-binding (PTR/lectican) family that organizes the neural extracellular matrix and whose proteolytic processing is a key determinant of glioma invasiveness. BCAN exists as secreted and GPI-anchored isoforms, and its cleavage at Glu395-Ser396 by ADAMTS4 generates N- and C-terminal fragments that each promote glioma cell invasion and tumor progression in vivo; a cleavage-resistant mutant abolishes these pro-invasive effects (PMID:10801887, PMID:18398576, PMID:11585735). In gliomas, additional underglycosylated and oversialylated isoforms associate with the tumor cell surface through a non-GPI mechanism and are selectively expressed in high-grade tumors (PMID:12799382, PMID:16061654). In normal brain, astrocyte-secreted brevican contributes to perineuronal net integrity, synapse stability, and nerve conduction, as demonstrated by a BCAN deletion causing paroxysmal hypertonicity (episodic falling syndrome) in dogs (PMID:21821125).

1. 1994 Medium

   Identification of BCAN as a novel brain-restricted hyaluronan-binding proteoglycan established the gene's ECM identity and CNS specificity, opening the question of its functional role in neural tissue.

   Evidence cDNA cloning, sequence homology, and Northern blot/in situ expression profiling in rat brain

   PMID:7512973

   Open questions at the time

   • No functional assays performed; role inferred from domain architecture only
   • Expression profiling limited to rodent
2. 1995 Medium

   Temporal coincidence of BCAN expression with gliogenesis rather than neurogenesis suggested a developmental role in glial lineage specification, raising the question of whether BCAN is functionally required for gliogenesis.

   Evidence In situ hybridization and immunohistochemistry during rat CNS development

   PMID:7869103

   Open questions at the time

   • Correlative timing only; no loss-of-function test of gliogenesis requirement
   • No mechanism linking BCAN to progenitor cell fate
3. 1999 Medium

   Discovery of secreted and GPI-anchored BCAN isoforms, with selective upregulation of the secreted form after brain injury, established isoform-specific regulation and implicated BCAN in the gliotic response.

   Evidence Immunoblotting, RNase protection assay, GPI-anchor characterization, adult rat stab-wound model

   PMID:10364444

   Open questions at the time

   • No loss-of-function to test whether secreted isoform upregulation is required for gliosis
   • Mechanism of isoform-specific transcriptional regulation unknown
4. 2000 High

   Identification of ADAMTS4 as the protease cleaving BCAN at Glu395-Ser396 in glioma cells defined the specific proteolytic event central to BCAN processing, setting up the question of whether cleavage is functionally required for invasion.

   Evidence Neoepitope antibody, protease inhibitor profiling, RT-PCR, and immunoblotting of CNS-1 glioma conditioned medium

   PMID:10801887

   Open questions at the time

   • Cleavage shown in one glioma cell line only
   • Functional consequence of cleavage not yet tested
5. 2001 Medium

   Overexpression of full-length BCAN or either cleavage fragment enhanced glioma aggressiveness in vivo, establishing that both upregulation and proteolytic processing of BCAN promote tumor invasion.

   Evidence Stable transfection of glioma cells, intracranial rat graft model, survival analysis

   PMID:11585735

   Open questions at the time

   • Gain-of-function only; no knockdown to test necessity
   • Mechanism by which cleavage fragments promote invasion unknown
6. 2003 Medium

   Discovery of an underglycosylated, membrane-associated BCAN isoform (B/b130) as the predominant form in glioma revealed that post-translational glycan modification diversifies BCAN cell-surface biology beyond the canonical secreted/GPI dichotomy.

   Evidence Subcellular fractionation, glycosidase treatment, immunoblotting in rat glioma model

   PMID:12799382

   Open questions at the time

   • Membrane-association mechanism for the non-GPI form unresolved
   • Functional contribution of underglycosylated isoform to invasion not directly tested
7. 2005 Medium

   Identification of glioma-specific oversialylated and hypoglycosylated BCAN isoforms that correlate with tumor grade showed that aberrant glycosylation marks aggressive tumors and could serve as biomarkers.

   Evidence Glycan characterization, surface biotinylation, GPI-anchor disruption, human glioma tissue analysis

   PMID:16061654

   Open questions at the time

   • Causal role of altered glycosylation in invasion not demonstrated
   • Mechanism of non-GPI cell-surface retention still unknown
8. 2008 High

   A cleavage-resistant BCAN mutant failed to enhance invasion in vitro or tumor progression in vivo, definitively establishing that ADAMTS-mediated cleavage at Glu395-Ser396 is necessary — not merely permissive — for BCAN's pro-invasive activity.

   Evidence Site-directed mutagenesis (396SRG→NVY), in vitro invasion assay, intracranial mouse glioma model

   PMID:18398576

   Open questions at the time

   • Downstream signaling pathways engaged by cleavage fragments remain unidentified
   • Whether other ADAMTS family members contribute to cleavage in vivo is untested
9. 2011 Medium

   A 15.7 kb BCAN deletion causing episodic falling syndrome in dogs provided the first genetic evidence that BCAN is required for normal neuronal function, linking it to perineuronal net integrity and synaptic/conduction stability.

   Evidence GWAS, targeted resequencing, deletion breakpoint mapping in Cavalier King Charles Spaniels

   PMID:21821125

   Open questions at the time

   • Canine model; no human Mendelian disorder confirmed
   • No rescue experiment to prove causality of the deletion alone
   • Specific perineuronal net structural defect not visualized
10. 2017 High

    CRISPR-engineered BCAN-NTRK1 fusion proved to be an oncogenic driver of high-grade glioma and conferred sensitivity to TRK inhibition, demonstrating that the BCAN locus participates in oncogenic rearrangements beyond its ECM functions.

    Evidence CRISPR somatic engineering of chromosomal deletion in mouse neural progenitors, in vivo tumorigenesis, entrectinib treatment

    PMID:28695888

    Open questions at the time

    • Oncogenic activity driven by NTRK1 kinase domain, not BCAN protein function per se
    • Frequency and clinical significance of BCAN-NTRK1 fusions in human glioma cohorts incompletely characterized

• The downstream signaling pathways through which BCAN cleavage fragments promote glioma invasion, the molecular basis of non-GPI membrane association of underglycosylated isoforms, and BCAN's precise structural role within perineuronal nets remain unresolved.
• No receptor or signaling cascade identified for BCAN cleavage fragments
• Structural basis of BCAN incorporation into perineuronal nets not determined
• No conditional knockout in adult mammalian brain to separate developmental from maintenance roles